Skip to content
Open access

PRO-C6 and endotrophin are associated with cardiac remodelling and adverse outcomes in HFpEF: data from the prospective NETDiamond cohort

Oct 2026 · European Heart Journal · Vol 47 · 0 citations

Abstract

Heart failure with preserved ejection fraction (HFpEF) is characterized by extracellular matrix (ECM) remodelling and fibrosis, but clinically useful circulating biomarkers reflecting these processes remain limited. To assess whether circulating ECM-derived biomarkers (PRO-C3, PRO-C6 and endotrophin) are associated with HFpEF, key clinical HF features, and adverse outcomes. In this prospective single-centre NETDiamond cohort analysis, plasma PRO-C3, PRO-C6 and endotrophin were measured using specific enzyme-linked immunosorbent assays (Nordic Bioscience) in controls (n=15) and patients with HFpEF (n=78). Biomarker levels were compared between groups, and in HFpEF their associations with clinical, laboratory and echocardiographic variables, as well as a composite HF endpoint (cardiovascular death, HF hospitalization, or acute HF episode), were evaluated using Cox regression with adjusted models including age, sex, creatinine and BNP. Circulating endotrophin was higher in HFpEF versus controls (p=0.0046; exact p=0.0040), whereas PRO-C3 and PRO-C6 were not significantly different. In HFpEF, higher PRO-C6 and endotrophin tertiles were associated with a more adverse clinical profile, including higher high-sensitivity troponin I, worse renal function, and adverse remodelling/diastolic dysfunction indices (including higher LVMI and E/e′); PRO-C6 tertiles were also associated with lower LVEF and higher LAVI, while endotrophin tertiles were associated with higher pulse wave velocity. During follow-up in HFpEF (n=78), 28 HF composite endpoint events occurred. PRO-C6 and endotrophin were associated with higher event risk. In adjusted models, PRO-C6 (HR 3.41, 95% CI 1.22 to 9.53; p=0.019) and endotrophin (HR 2.74, 95% CI 1.20 to 6.22; p=0.016) remained significantly associated with the composite endpoint. Tertile analyses were concordant, with progressively higher risk across PRO-C6 and endotrophin tertiles. In this prospective single-centre HFpEF cohort, PRO-C6 and endotrophin identified a higher-risk HFpEF phenotype characterized by myocardial injury and adverse remodelling, and were independently associated with adverse outcomes. These findings support the type VI collagen/endotrophin axis as a promising pathway for HFpEF risk stratification and may also help identify biologically relevant, potentially targetable mechanisms of disease.

Read PDF

Similar papers

Open access Oct 2026

Statin treatment long-term prognostic impact and its association with immune-inflammatory biomarkers levels in acute heart failure with preserved ejection fraction

Heart failure with preserved ejection fraction (HFpEF) is characterized by diastolic dysfunction of left ventricle. There is evidence on the role of inflammation in the pathophysiology of HFpEF, however this knowledge is yet to be utilized in clinical practice. We conducted a study to evaluate the associat...

K. Stepien, P. Rostoff, A. Karcińska et al. · 0 citations
Open access Oct 2026

Atrial fibrillation in HFpEF and HFmrEF Is linked to a distinct systemic proteomic phenotype

In heart failure with preserved or mildly reduced ejection fraction (HFpEF/HFmrEF), atrial fibrillation (AF) is common and prognostically relevant. Beyond electrical instability, AF is linked to structural atrial remodelling and adverse outcomes. Emerging evidence suggests that atrial remodelling in HFpEF/HFmrEF...

J. Vogel, S. Jura, S. Settelmeier et al. · 0 citations
Nov 2026

miR-200c-3p: An Adjunct Chronic Heart Failure Risk Marker Modulating Cardiomyocyte Hypertrophic Transcription and Cardiac Fibroblast Fibrosis.

This study evaluated circulating microRNA-200c-3p (miR-200c-3p) for diagnosis and prognosis in chronic heart failure (CHF) and its regulatory roles in cardiomyocyte hypertrophy and myocardial fibrosis in vitro. A single-center prospective cohort included 150 CHF patients and 80 healthy controls, with CHF stratified int...

Fei Li, Bao-Feng Jiang · 0 citations
#small language model Review Open access Sep 2026

Soluble ST2 dynamic changes predict the cardiorenal protective efficacy of arni in patients with heart failure with preserved ejection fraction: a meta-analysis

Background: Heart failure with preserved ejection fraction (HFpEF) accounts for approximately 50% of HF cases, predominantly affecting older adults with comorbidities such as hypertension, diabetes, and obesity. Despite the breakthrough provided by angiotensin receptor-neprilysin inhibitors (ARNI), approximately 30%...

Yong Il Ho, Zhi-Quan Wang, Jong-Suk Mun et al. · 0 citations
Open access Nov 2026

MR-proANP, but Not Copeptin, Predicts Cardiovascular Events and Mortality in Type 1 Diabetes: A Prospective Cohort Study

Background/Objectives: MR-proANP and copeptin are biomarkers of cardiovascular stress and individuals with type 1 diabetes are at increased cardiovascular risk. We aimed to investigate the associations of MR-proANP and copeptin with major adverse cardiovascular events (MACEs) and all-cause mortality in individuals with...

Emilia Gauffin, Emma Paulsson, H. Arnqvist et al. · 0 citations
Open access Nov 2026

Angiopoietin-Like 4 (ANGPTL4) Protein and Its Relation to Lipids Challenges the Prognostic Performance of B-Type Natriuretic Peptide (BNP) Transcontinentally in Patients with Suspected Coronary Chest Pain, Suggesting Their Combined Use in Risk Prediction

BNP is predominantly synthesized in the ventricular myocardium in response to ventricular distension. ANGPTL4 modulates lipid metabolism, vascular integrity and angiogenesis. Both biomarkers serve as prognostic indicators in acute coronary syndrome (ACS). The purpose of this study is to compare the prognostic weighting...

D. Nilsen, R. Leondelafuente, R. Aarsetoey et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.